Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx Route To Re-Approval Outlined By FDA As Merck Mulls Options

Executive Summary

Conflicting opinions from FDA advisory committee members on the safety of Vioxx necessitates additional committee consideration prior to re-approval of the COX-2 inhibitor, an FDA memo states

You may also be interested in...



GSK’s COX-2 Plans: Complete Cardio Safety Study, Test Efficacy Of Low Doses

GlaxoSmithKline is pushing back the anticipated NDA filing date for its Phase II COX-2 inhibitor to complete a cardiovascular safety study at the request of FDA, CEO J.P. Garnier said during an earnings call April 28

GSK’s COX-2 Plans: Complete Cardio Safety Study, Test Efficacy Of Low Doses

GlaxoSmithKline is pushing back the anticipated NDA filing date for its Phase II COX-2 inhibitor to complete a cardiovascular safety study at the request of FDA, CEO J.P. Garnier said during an earnings call April 28

COX-2 Review Highlights “Conundrum” Of FDA Drug Safety Regulation

FDA's summary of the COX-2 inhibitor safety review underscores the "conundrum" posed by drug safety regulation

Related Content

Topics

UsernamePublicRestriction

Register

PS045726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel